Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.

× No keyword cloud information.

8 in total

1. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Authors: David E Spaner; Guizhei Wang; Lindsay McCaw; Yanmei Li; Patricia Disperati; Mary-Ann Cussen; Yonghong Shi
Journal: Haematologica Date: 2016-01-27 Impact factor: 9.941

Review 2. Role of bone marrow adipocytes in leukemia and chemotherapy challenges.

Authors: Azin Samimi; Majid Ghanavat; Saeid Shahrabi; Shirin Azizidoost; Najmaldin Saki
Journal: Cell Mol Life Sci Date: 2019-02-04 Impact factor: 9.261

Review 3. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors: S N Malek
Journal: Oncogene Date: 2012-09-24 Impact factor: 9.867

4. Dexamethasone alleviates tumor-associated brain damage and angiogenesis.

Authors: Zheng Fan; Tina Sehm; Manfred Rauh; Michael Buchfelder; Ilker Y Eyupoglu; Nicolai E Savaskan
Journal: PLoS One Date: 2014-04-08 Impact factor: 3.240

5. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.

Authors: Veronica L Martinez Marignac; Sarah Smith; Nader Toban; Miguel Bazile; Raquel Aloyz
Journal: Oncotarget Date: 2013-12

Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.

1. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Review 2. Role of bone marrow adipocytes in leukemia and chemotherapy challenges.

Review 3. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

4. Dexamethasone alleviates tumor-associated brain damage and angiogenesis.

5. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.

6. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.

7. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.

Review 8. The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells.